Difference between revisions of "Smith DC, et al. Clin. Cancer Res. (2014) cited as Ref 595 in DOI: 10.1038/s41392-020-0110-5 (Q9858)"
Jump to navigation
Jump to search
(Added link to [sliswiki]: Smith DC, et al. Clin. Cancer Res. (2014) cited as Ref 595 in DOI: 10.1038/s41392-020-0110-5, #quickstatements; #temporary_batch_1589988087154) |
(Created claim: Page(s) (P105): 6295-6303, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / First Author string | |||||||||||||||
| + | Smith DC | ||||||||||||||
| Property / First Author string: Smith DC / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / DOI Identifier | |||||||||||||||
| + | |||||||||||||||
| Property / DOI Identifier: 10.1158/1078-0432.CCR-14-1373 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 25324140 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2014
| ||||||||||||||
| Property / Publication Date: 2014 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Clin. Cancer Res. | ||||||||||||||
| Property / Published In Name String: Clin. Cancer Res. / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 20 | ||||||||||||||
| Property / Volume: 20 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors (English) | ||||||||||||||
| Property / title: A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 6295-6303 | ||||||||||||||
| Property / Page(s): 6295-6303 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Latest revision as of 15:46, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Smith DC, et al. Clin. Cancer Res. (2014) cited as Ref 595 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Smith DC
0 references
2014
0 references
Clin. Cancer Res.
0 references
20
0 references
A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors (English)
0 references
6295-6303
0 references
